Bright Minds Biosciences (XCNQ:DRUG) Current Accrued Expense : C$0.02 Mil (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Bright Minds Biosciences Current Accrued Expense?

Bright Minds Biosciences's Current Accrued Expense for the quarter that ended in Dec. 2024 was C$0.02 Mil.

Bright Minds Biosciences's quarterly Current Accrued Expense increased from Jun. 2024 (C$0.02 Mil) to Sep. 2024 (C$0.04 Mil) but then declined from Sep. 2024 (C$0.04 Mil) to Dec. 2024 (C$0.02 Mil).

Bright Minds Biosciences's annual Current Accrued Expense declined from Sep. 2022 (C$0.16 Mil) to Sep. 2023 (C$0.03 Mil) but then increased from Sep. 2023 (C$0.03 Mil) to Sep. 2024 (C$0.04 Mil).

Bright Minds Biosciences Current Accrued Expense Historical Data

The historical data trend for Bright Minds Biosciences's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bright Minds Biosciences Current Accrued Expense Chart

Bright Minds Biosciences Annual Data

Trend

Sep20

Sep21

Sep22

Sep23

Sep24

Current Accrued Expense

0.01

0.04

0.16

0.03

0.04

Bright Minds Biosciences Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Current Accrued Expense	Get a 7-Day Free Trial															-	0.01	0.02	0.04	0.02

Bright Minds Biosciences Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Bright Minds Biosciences Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Bright Minds Biosciences's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Bright Minds Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bright Minds Biosciences Inc (XCNQ:DRUG) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

DRUG:USA

Address

19 Vestry Street, New York, NY, USA, 10013

Website

https://www.brightmindsbio.com

Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Executives

Jan Torleif Pedersen	Director
Nils Bottler	Director
Ryan Cheung	Senior Officer
Jeremy Fryzuk	Director
Alan Kozikowski	10% Security Holder, Director, Senior Officer
Ian Mcdonald	Director